Raymond James Financial
NTLA icon

Raymond James Financial’s Intellia Therapeutics NTLA Stock Holding History

Raymond James Financial’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8M Buy
699,390
+122,460
+21% +$1.71M ﹤0.01% 2009
2026
Q1 		$7.4M Buy
576,930
+175,269
+44% +$2.23M ﹤0.01% 2268
2025
Q4 		$3.61M Buy
401,661
+84,711
+27% +$1.17M ﹤0.01% 2776
2025
Q3 		$5.47M Buy
316,950
+18,239
+6% +$225K ﹤0.01% 2399
2025
Q2 		$2.8M Buy
298,711
+49,476
+20% +$406K ﹤0.01% 2810
2025
Q1 		$1.77M Sell
249,235
-161,842
-39% -$1.63M ﹤0.01% 3080
2024
Q4 		$4.79M Buy
+411,077
New +$6.42M ﹤0.01% 2359

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Raymond James Financial's NTLA Position: Q2 2026 in Review

Raymond James Financial increased its Intellia Therapeutics (NTLA) stake by 21% in Q2 2026, buying an estimated $1.71M and bringing the position to 699,390 shares worth $11.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2009.

Raymond James Financial first reported a position in NTLA in Q4 2024 and has held it in 7 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Raymond James Financial held 699,390 shares of Intellia Therapeutics worth $11.8M as of Q2 2026.
  • Raymond James Financial bought 122,460 Intellia Therapeutics shares in Q2 2026, an estimated $1.71M.
  • Intellia Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2009 holding.
  • Raymond James Financial first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.